To evaluate whether ATF5-CaP-rHDL induceany adverse effect during treatment, tumour-bearing mice received the sameATF5-CaP-rHDL treatment were also subjected to behavioural, physical andbiochemical effect assessment paralleled with administration with salinecontrols. The gene discussed is ATF5; the disease is neoplasm.